| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1016143285 |
| P356 | DOI | 10.1186/1475-2875-13-143 |
| P932 | PMC publication ID | 4021201 |
| P698 | PubMed publication ID | 24731288 |
| P5875 | ResearchGate publication ID | 261732929 |
| P50 | author | Sandra Duffy | Q56590200 |
| R. Kiplin Guy | Q67426629 | ||
| Nikhil Rautela | Q96112398 | ||
| Santiago Ferrer | Q98652808 | ||
| Pavithra Viswanath | Q104744898 | ||
| Michele C Connelly | Q114415532 | ||
| Julie Lotharius | Q114415540 | ||
| Francisco Javier Gamo Benito | Q114415542 | ||
| Balachandra Bandodkar | Q114415544 | ||
| Sowmya Bharath | Q114415545 | ||
| Iñigo Angulo-Barturen | Q28913768 | ||
| Vicky M. Avery | Q42707018 | ||
| Timothy N C Wells | Q55182082 | ||
| P2093 | author name string | Tanya Parkinson | |
| Jörg J Möhrle | |||
| Julie Clark | |||
| P2860 | cites work | Plasmodium falciparum: Assessment of in vitro growth by [3H]hypoxanthine incorporation | Q70238538 |
| APT drug R&D: the right active ingredient in the right presentation for the right therapeutic use | Q84481949 | ||
| Fast mouse PK (Fast PK): a rapid screening method to increase pharmacokinetic throughput in pre-clinical drug discovery | Q84567573 | ||
| Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine | Q21033481 | ||
| Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness | Q21144517 | ||
| Thousands of chemical starting points for antimalarial lead identification | Q24289329 | ||
| Spiroindolones, a potent compound class for the treatment of malaria | Q24606915 | ||
| Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug | Q24613311 | ||
| Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes | Q24651549 | ||
| Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders | Q24657681 | ||
| Global phenotypic screening for antimalarials | Q26824875 | ||
| Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening | Q27306843 | ||
| Human malaria parasites in continuous culture | Q28131626 | ||
| Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole | Q28137852 | ||
| Targeting protein kinases in the malaria parasite: update of an antimalarial drug target | Q28257406 | ||
| Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso | Q28472182 | ||
| A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes | Q28472751 | ||
| A research agenda for malaria eradication: drugs | Q28476806 | ||
| The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment | Q28730788 | ||
| Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique | Q29616826 | ||
| Chemical genetics of Plasmodium falciparum | Q29617272 | ||
| Protein kinases as targets for anti-parasitic chemotherapy | Q30828981 | ||
| New anti-tuberculosis agents amongst known drugs | Q30872520 | ||
| A clinical drug library screen identifies astemizole as an antimalarial agent | Q33248659 | ||
| Searching for new antimalarial therapeutics amongst known drugs | Q33252500 | ||
| Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B | Q33303627 | ||
| Repositioning of an existing drug for the neglected tropical disease Onchocerciasis | Q33530297 | ||
| Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening | Q34122581 | ||
| The use of the 2 substituted 5-nitroimidazole, Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice | Q34265044 | ||
| Quinolone-3-diarylethers: a new class of antimalarial drug. | Q34334269 | ||
| Methotrexate is highly potent against pyrimethamine-resistant Plasmodium vivax | Q34763470 | ||
| A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers | Q34770054 | ||
| A high-throughput screen targeting malaria transmission stages opens new avenues for drug development | Q34833899 | ||
| Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug | Q35585226 | ||
| A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy | Q35652903 | ||
| The global pipeline of new medicines for the control and elimination of malaria | Q36320249 | ||
| Mammalian interphase cdks: dispensable master regulators of the cell cycle | Q36796448 | ||
| New medicines to improve control and contribute to the eradication of malaria | Q37615897 | ||
| Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies | Q37616407 | ||
| Road towards new antimalarials - overview of the strategies and their chemical progress | Q37823625 | ||
| Hydroxychloroquine: from malaria to autoimmunity | Q37827403 | ||
| Drug repositioning for orphan diseases | Q37866927 | ||
| Drug repositioning in the treatment of malaria and TB. | Q37924298 | ||
| The role of antimalarial agents in the treatment of SLE and lupus nephritis | Q37947108 | ||
| Aurora kinase inhibitors: progress towards the clinic | Q37986455 | ||
| Antimalarials in the treatment of schistosomiasis. | Q38011217 | ||
| Artemisinin derivatives: a patent review (2006 - present). | Q38042732 | ||
| Antiretrovirals as antimalarial agents. | Q39469775 | ||
| Artemisinin resistance--the clock is ticking | Q39589862 | ||
| Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. | Q40815903 | ||
| Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy. | Q40815932 | ||
| The potential use of methotrexate in the treatment of falciparum malaria: in vitro assays against sensitive and multidrug-resistant falciparum strains. | Q41940877 | ||
| Anticancer agents against malaria: time to revisit? | Q42488257 | ||
| Methotrexate and aminopterin lack in vivo antimalarial activity against murine malaria species | Q43881567 | ||
| Haemolysis risk in methylene blue treatment of G6PD-sufficient and G6PD-deficient West-African children with uncomplicated falciparum malaria: a synopsis of four RCTs | Q43929062 | ||
| Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso | Q43931017 | ||
| Malaria. Did they really say ... eradication? | Q44139004 | ||
| Effect of cyclosporine on parasitemia and survival of Plasmodium berghei infected mice | Q46369661 | ||
| Quantitative measurement of Plasmodium-infected erythrocytes in murine models of malaria by flow cytometry using bidimensional assessment of SYTO-16 fluorescence | Q47877591 | ||
| The metabolism of platelet-activating factor in severe and cerebral malaria | Q48025992 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| P304 | page(s) | 143 | |
| P577 | publication date | 2014-04-14 | |
| P1433 | published in | Malaria Journal | Q15749954 |
| P1476 | title | Repositioning: the fast track to new anti-malarial medicines? | |
| P478 | volume | 13 |
Search more.